drugset / Trial / NCT05741294
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.
Timeline
- Start
- 2023-01-20
- Primary completion
- 2024-01-19
- Completion
- 2024-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tirbanibulin | Small molecule | 2.5 mg | Topical |